The precision question nobody puts to a body-composition report
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.
Trial design
Page 15 of 32 of this archive, newest first.
From the floor in Shenzhen: 9 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Two sessions a week, and the evidence behind the prescription
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
The out-of-range flag is a statistical convention with a printer attached
A twelve-analyte panel in a perfectly healthy person has roughly even odds of producing at least one flagged result.
From the floor in Hong Kong: 13 posters, one theme
Reported from the sessions, and from the two hours afterwards.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Vitamin D, adiposity, and a volume-of-distribution problem
Micronutrient guidance for this drug class is borrowed almost entirely from post-bariatric surveillance, where the anatomy is different and the deficiency mechanisms are not…
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What TRIUMPH-1 tells us about maintenance, and what it does not
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Qingdao: 3 posters, one theme
Reported from the sessions, and from the two hours afterwards.
From the floor in Nantong: 15 posters, one theme
Reported from the sessions, and from the two hours afterwards.
From the floor in Shenzhen: 24 posters, one theme
Reported from the sessions, and from the two hours afterwards.
A design note on withdrawal trials, and why the run-in matters
The regain trajectories, arm by arm, with the estimands named.
Load, not cardio: the distinction the general advice keeps losing
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.